Indaptus Therapeutics (INDP) Competitors

$2.09 -0.06 (-2.79%)

Closing price 04:00 PM Eastern

Extended Trading

$2.08 -0.01 (-0.72%)

As of 04:41 PM Eastern

INDP vs. NRSN, VIRI, TPST, JSPR, and BRNS

Should you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include NeuroSense Therapeutics (NRSN), Virios Therapeutics (VIRI), Tempest Therapeutics (TPST), Jasper Therapeutics (JSPR), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical products" industry.

How does Indaptus Therapeutics compare to NeuroSense Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

: Indaptus Therapeutics has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.
: In the previous week, NeuroSense Therapeutics' average media sentiment score of 0.57 beat Indaptus Therapeutics' score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
Indaptus Therapeutics Neutral
NeuroSense Therapeutics Positive
: NeuroSense Therapeutics has a consensus target price of $8.50, indicating a potential upside of 794.93%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Indaptus Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
NeuroSense Therapeutics
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

1 Strong Buy rating(s)
2.60
: NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Indaptus Therapeutics N/A N/A -$20.85M -$24.13 N/A
NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A
: 7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 23.6% of Indaptus Therapeutics shares are owned by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: NeuroSense Therapeutics' return on equity of 0.00% beat Indaptus Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Indaptus Therapeutics N/A -939.67% -293.64%
NeuroSense Therapeutics N/A N/A N/A

Company	Overall Sentiment
Indaptus Therapeutics	Neutral
NeuroSense Therapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$24.13	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-939.67%	-293.64%
NeuroSense Therapeutics	N/A	N/A	N/A

Summary

NeuroSense Therapeutics beats Indaptus Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Virios Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

: Indaptus Therapeutics has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500.
: In the previous week, Indaptus Therapeutics' average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score.
Company Overall Sentiment
Indaptus Therapeutics Neutral
Virios Therapeutics Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Virios Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Virios Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Indaptus Therapeutics N/A N/A -$20.85M -$24.13 N/A
Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A
: 7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 23.6% of Indaptus Therapeutics shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
: Virios Therapeutics' return on equity of -130.33% beat Indaptus Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Indaptus Therapeutics N/A -939.67% -293.64%
Virios Therapeutics N/A -130.33% -115.00%

Company	Overall Sentiment
Indaptus Therapeutics	Neutral
Virios Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$24.13	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-939.67%	-293.64%
Virios Therapeutics	N/A	-130.33%	-115.00%

Summary

Virios Therapeutics beats Indaptus Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Tempest Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

: 7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 23.6% of Indaptus Therapeutics shares are owned by company insiders. Comparatively, 6.3% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: Tempest Therapeutics' return on equity of -309.60% beat Indaptus Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Indaptus Therapeutics N/A -939.67% -293.64%
Tempest Therapeutics N/A -309.60% -115.81%
: Indaptus Therapeutics has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -1.75, indicating that its share price is 275% less volatile than the S&P 500.
: In the previous week, Tempest Therapeutics had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 1 mentions for Tempest Therapeutics and 0 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 0.00 equaled Tempest Therapeutics'average media sentiment score.
Company Overall Sentiment
Indaptus Therapeutics Neutral
Tempest Therapeutics Neutral
: Tempest Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Indaptus Therapeutics N/A N/A -$20.85M -$24.13 N/A
Tempest Therapeutics N/A N/A -$26.26M -$6.64 N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Tempest Therapeutics
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.50

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-939.67%	-293.64%
Tempest Therapeutics	N/A	-309.60%	-115.81%

Company	Overall Sentiment
Indaptus Therapeutics	Neutral
Tempest Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$24.13	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.64	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tempest Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Tempest Therapeutics beats Indaptus Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Jasper Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

: Jasper Therapeutics has a consensus target price of $19.88, indicating a potential upside of 1,956.81%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Indaptus Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Jasper Therapeutics
1 Sell rating(s)

5 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.42
: Indaptus Therapeutics has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 3.07, indicating that its share price is 207% more volatile than the S&P 500.
: Jasper Therapeutics' return on equity of -372.18% beat Indaptus Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Indaptus Therapeutics N/A -939.67% -293.64%
Jasper Therapeutics N/A -372.18% -153.67%
: 7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 23.6% of Indaptus Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: In the previous week, Indaptus Therapeutics' average media sentiment score of 0.00 equaled Jasper Therapeutics'average media sentiment score.
Company Overall Sentiment
Indaptus Therapeutics Neutral
Jasper Therapeutics Neutral
: Jasper Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Indaptus Therapeutics N/A N/A -$20.85M -$24.13 N/A
Jasper Therapeutics N/A N/A -$75.80M -$4.60 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jasper Therapeutics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-939.67%	-293.64%
Jasper Therapeutics	N/A	-372.18%	-153.67%

Company	Overall Sentiment
Indaptus Therapeutics	Neutral
Jasper Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$24.13	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$4.60	N/A

Summary

Jasper Therapeutics beats Indaptus Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Barinthus Biotherapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

: Indaptus Therapeutics has lower revenue, but higher earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Barinthus Biotherapeutics $14.97M 1.79 -$66.43M -$1.29 N/A
Indaptus Therapeutics N/A N/A -$20.85M -$24.13 N/A
: Barinthus Biotherapeutics has a beta of -0.43, indicating that its stock price is 143% less volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.
: Barinthus Biotherapeutics currently has a consensus target price of $4.00, indicating a potential upside of 510.69%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Barinthus Biotherapeutics is more favorable than Indaptus Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Barinthus Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Indaptus Therapeutics
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Barinthus Biotherapeutics' return on equity of -63.83% beat Indaptus Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Barinthus Biotherapeutics N/A -63.83% -48.77%
Indaptus Therapeutics N/A -939.67% -293.64%
: In the previous week, Barinthus Biotherapeutics had 4 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 4 mentions for Barinthus Biotherapeutics and 0 mentions for Indaptus Therapeutics. Barinthus Biotherapeutics' average media sentiment score of 0.75 beat Indaptus Therapeutics' score of 0.00 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Barinthus Biotherapeutics Positive
Indaptus Therapeutics Neutral
: 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 8.0% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.79	-$66.43M	-$1.29	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$24.13	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
Indaptus Therapeutics	N/A	-939.67%	-293.64%

Company	Overall Sentiment
Barinthus Biotherapeutics	Positive
Indaptus Therapeutics	Neutral

Summary

Barinthus Biotherapeutics beats Indaptus Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Indaptus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDP vs. The Competition

Export

Metric	Indaptus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.82M	$3.09B	$6.25B	$11.77B
Dividend Yield	N/A	1.92%	2.74%	5.26%
P/E Ratio	-0.09	12.85	24.91	23.23
Price / Sales	N/A	278.28	504.56	75.49
Price / Cash	N/A	55.25	43.30	53.90
Price / Book	1.49	4.30	9.67	6.69
Net Income	-$20.85M	$72.19M	$3.55B	$332.64M
7 Day Performance	-35.89%	2.03%	1.70%	2.01%
1 Month Performance	30.63%	6.42%	5.62%	9.19%
1 Year Performance	-83.81%	37.74%	34.42%	39.59%

Indaptus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDP Indaptus Therapeutics	0.2304 of 5 stars	$2.09 -2.8%	N/A	N/A	$4.82M	N/A	N/A	6	Upcoming Earnings High Trading Volume
NRSN NeuroSense Therapeutics	2.0795 of 5 stars	$0.80 -0.7%	$8.50 +958.4%	N/A	$26.15M	N/A	N/A	10
VIRI Virios Therapeutics	N/A	$1.35 +0.7%	N/A	N/A	$26.00M	N/A	N/A	5
TPST Tempest Therapeutics	0.7587 of 5 stars	$1.74 +3.0%	N/A	N/A	$24.96M	N/A	N/A	20	Upcoming Earnings
JSPR Jasper Therapeutics	2.5462 of 5 stars	$0.89 -4.2%	$19.88 +2,132.4%	N/A	$24.93M	N/A	N/A	20	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDP) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indaptus Therapeutics (INDP) Competitors

INDP vs. NRSN, VIRI, TPST, JSPR, and BRNS

How does Indaptus Therapeutics compare to NeuroSense Therapeutics?

Summary

How does Indaptus Therapeutics compare to Virios Therapeutics?

Summary

How does Indaptus Therapeutics compare to Tempest Therapeutics?

Summary

How does Indaptus Therapeutics compare to Jasper Therapeutics?

Summary

How does Indaptus Therapeutics compare to Barinthus Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indaptus Therapeutics (INDP) Competitors

INDP vs. NRSN, VIRI, TPST, JSPR, and BRNS

How does Indaptus Therapeutics compare to NeuroSense Therapeutics?

Summary

How does Indaptus Therapeutics compare to Virios Therapeutics?

Summary

How does Indaptus Therapeutics compare to Tempest Therapeutics?

Summary

How does Indaptus Therapeutics compare to Jasper Therapeutics?

Summary

How does Indaptus Therapeutics compare to Barinthus Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools